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Summary
 
To localize the immunoglobulin (Ig)-binding regions of the human Fc
 
a
 
 receptor (Fc
 
a
 
RI, CD89)
and the bovine Fc
 
g
 
2 receptor (bFc
 
g
 
2R), chimeric receptors were generated by exchanging com-
parable regions between these two proteins. Fc
 
a
 
RI and bFc
 
g
 
2R are highly homologous and are
more closely related to each other than to other human and bovine FcRs. Nevertheless, they are
functionally distinct in that Fc
 
a
 
RI binds human IgA (hIgA) but not bovine IgG2 (bIgG2),
whereas bFc
 
g
 
2R binds bIgG2 but not hIgA. Fc
 
a
 
RI and bFc
 
g
 
2R possess extracellular regions
consisting of two Ig-like domains, a membrane-distal extracellular domain (EC1), a membrane-
proximal EC domain (EC2), a transmembrane region, and a short cytoplasmic tail. Chimeras
constructed by exchanging complete domains between these two receptors were transfected to
COS-1 cells and assayed for their ability to bind hIgA- or bIgG2-coated beads. The results
showed that the Ig-binding site of both Fc
 
a
 
RI and bFc
 
g
 
2R is located within EC1. Supporting
this observation, monoclonal antibodies that blocked IgA binding to Fc
 
a
 
RI were found to rec-
ognize epitopes located in this domain. In terms of FcR–Ig interactions characterized thus far, this
location is unique and surprising because it has been shown previously that leukocyte Fc
 
g
 
Rs and
Fc
 
e
 
RI bind Ig via sites principally located in their EC2 domains.
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g
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I
 
mmunoglobulin (Ig) Fc receptors (FcRs) expressed on
phagocytic cells provide a crucial link between the hu-
moral and cellular branches of the immune system. Ligation
of FcRs by antigen-bound Ig leads to cellular activation and
triggering of powerful effector mechanisms (1, 2). In humans
and other mammals, IgA predominates in mucosae and,
furthermore, comprises a substantial proportion of the circu-
lating Ig pool. At mucosal surfaces IgA provides a first-line
protective function, termed immune exclusion, whereby it
inhibits microbial colonization on epithelial cells and pene-
tration of harmful antigens. In addition, the protective func-
tion of IgA both in mucosa and in the circulation may be re-
inforced by interaction of IgA-complexed antigens with the
myeloid Fc
 
a
 
RI (CD89)(3, 4). Fc
 
a
 
RI is expressed on mono-
cytes, macrophages, polymorphonuclear granulocytes, and
eosinophils, and its cross-linking triggers a variety of immu-
nological effector functions, including phagocytosis, antibody-
dependent cellular cytotoxicity, and release of inflammatory
mediators and cytokines (3–6).
Among FcRs characterized until now, Fc
 
a
 
RI is most
closely related to the bovine Fc receptor for IgG2 (bFc
 
g
 
2R)
 
1
 
expressed on monocytes and granulocytes. In fact, these two
FcRs are more closely related to each other than to any
known human or bovine FcRs (7). More recently, it has
been shown that Fc
 
a
 
RI and bFc
 
g
 
2R are members of a
new gene family that apparently evolved from a common
ancestral gene. Other human genes belonging to this family
include the natural killer cell inhibitory receptors (KIRs),
the Ig-like transcripts (ILTs), the leukocyte and monocyte/
macrophage Ig-like receptors (LIRs, MIRs), LAIR-1, and
HM18 (8–13). These genes are located close to the Fc
 
a
 
RI
gene within the so-called leukocyte receptor complex on
chromosome 19q13.4 (13–15). Several murine members of
the same gene family, gp49B1 (a structural homologue of
 
1
 
Abbreviations used in this paper:
 
 b, bovine; EC, extracellular; GAM, goat
anti–mouse; GFP, green fluorescent protein; KIR, natural killer cell in-
hibitory receptor; TM/C, transmembrane/cytoplasmic. 
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human KIRs), and the paired Ig-like receptors A and B
(PIR-A and PIR-B), have also been described (16–18).
Fc
 
a
 
RI and bFc
 
g
 
2R are both transmembrane glycoproteins
composed of two extracellular (EC) Ig-like domains (EC1 and
EC2), a transmembrane region containing a charged arginine
residue, and a short cytoplasmic tail devoid of signaling mo-
tifs (7, 19). Signal transduction via Fc
 
a
 
RI is mediated via
the FcR 
 
g
 
 chain, which associates with Fc
 
a
 
RI through the
charged arginine residue within its transmembrane domain
but does not affect its affinity for IgA (20–23). Despite the
high level of amino acid identity (41%) within the EC and
transmembrane regions of Fc
 
a
 
RI and bFc
 
g
 
2R, these two
receptors are functionally quite distinct in that Fc
 
a
 
RI binds
IgA but not bIgG2, whereas bFc
 
g
 
2R binds bIgG2 but not
IgA. Therefore, to map the ligand-binding domains of
these two FcRs we utilized their high degree of identity and
exchanged homologous regions between them. Based on
knowledge of interactions between other two-domain
FcRs (Fc
 
g
 
RII, Fc
 
g
 
RIII, and Fc
 
e
 
RI) with their respective
ligands (IgG or IgE), we expected the Ig-binding sites to be
located within the membrane-proximal EC2 domain (24–
30). Surprisingly, however, our results demonstrated that
the ligand-binding region of both Fc
 
a
 
RI and bFc
 
g
 
2R is
located in their membrane-distal EC1 domain. In part, this
finding probably reflects the evolutionary development of
Fc
 
a
 
RI and bFc
 
g
 
2R from an ancestral gene distinct from
the putative Fc
 
g
 
R/Fc
 
e
 
R precursor.
 
Materials and Methods
 
Cell Culture.
 
COS-1 cells were maintained in DMEM (Bio-
Whittaker) supplemented with 10% FCS, 1 mM L-glutamine,
and 50 
 
m
 
g/ml gentamycin (Life Technologies, UK). The murine
IIA1.6 B cell line that coexpresses Fc
 
a
 
RI and the FcR 
 
g
 
 chain
has been described previously (21).
 
cDNAs and Construction of Chimeric FcRs.
 
cDNAs encoding the
complete Fc
 
a
 
RI coding region and a mutant cDNA encoding a
soluble form of Fc
 
a
 
RI were gifts from Dr. C. Maliszewski (Im-
munex Corp., Seattle, WA) (19, 31). cDNA for bFc
 
g
 
2R has been
described previously (7). Chimeric cDNAs were constructed by
overlap extension PCR (21). Although the genomic structure of
bFc
 
g
 
2R is unknown, the high homology to Fc
 
a
 
RI allowed us to
infer intron–exon boundaries because amino acid residues that
link the Fc
 
a
 
RI exons are identical to those at comparable posi-
tions in bFc
 
g
 
2R (Fig. 1). Primers were thus designed to allow the
fusion of exons at these residues. To construct the bEC1
 
(1–50)
 
-
Fc
 
a
 
RI mutant, primers were designed to allow the fusion of the
first 50 amino acids of bFc
 
g
 
2R to Fc
 
a
 
RI at isoleucine 50; both
Fc
 
a
 
RI and bFc
 
g
 
2R have isoleucine residues at this position,
which lies almost exactly in the middle of the EC1 domains. The
integrity of all chimeric cDNAs was confirmed by sequence anal-
ysis. Chimeric FcR cDNAs were cloned into the pCDNA3
mammalian expression vector (Invitrogen, The Netherlands) be-
fore transfection. The pCMV-GFP plasmid, which directed the
expression of green fluorescent protein (GFP), was constructed
by inserting the CMV promoter region from pCDNA3 into the
multiple cloning site of the pEGFP-1 vector (Clontech).
 
Transfections.
 
COS-1 cells were transiently transfected with
2 
 
m
 
g chimeric FcR cDNA constructs by means of Fugene 6
transfection reagent (Boehringer Mannheim, Germany) accord-
 
ing to the manufacturer’s instructions. In some experiments, 1 
 
m
 
g
pCMV-GFP was cotransfected together with the FcR constructs.
Cells were incubated at 37
 
8
 
C in a humidified CO
 
2
 
 atmosphere
for 48 h before harvesting.
 
Ig-binding Assays.
 
Uncoated magnetic M-450 Dynabeads (Dy-
nal, Norway) were coated, according to the manufacturer’s
instructions, with either human serum IgA (hIgA) or bovine
IgG2 (bIgG2), which were purified as previously described (7,
32). Due to low transfection efficiency of some DNA constructs
(see Results), transfected COS-1 cells were first enriched for those
becoming positive for gene expression by cotransfection of the
FcR and pCMV-GFP constructs. Experiments showed that most
fluorescent (GFP
 
1
 
) cells had also taken up both plasmids, thus ex-
pressing the chimeric FcR together with GFP (see Results).
Therefore, binding assays were performed as follows: 5 
 
3
 
 10
 
4
 
GFP
 
1
 
 COS-1 cells (which had also been cotransfected with an
FcR construct) were purified in a FACSVantage
 
®
 
 cell sorter
(Becton Dickinson) and mixed with Ig-coated Dynabeads in a fi-
nal volume of 50 
 
m
 
l per well in V-bottomed microtiter plates.
After a 15-min incubation at room temperature, the plate was
spun at 50 
 
g
 
 for 1 min and incubated for an additional 45 min at
room temperature. Cells and beads were resuspended and exam-
ined for the presence of rosettes, using a combination of light and
fluorescent microscopy, in a Nikon Eclipse E800 microscope.
Rosettes were defined as GFP
 
1
 
 cells binding four or more Ig-
coated beads and at least 200 GFP
 
1
 
 COS-1 cells were counted
for each determination. For blocking studies, cells were incu-
bated with either mAb My43 (50 
 
m
 
l culture supernatant) or CC-
G24 (50 
 
m
 
l ascites fluid diluted 1:4) for 30 min at room tempera-
ture before the addition of Ig-coated beads.
 
Production and Purification of Recombinant Soluble Fc
 
a
 
RI.
 
A cDNA
that encodes a soluble form of Fc
 
a
 
RI was expressed in Chinese
hamster ovary cells by means of the pEE14 expression system
(Lonza, UK), and the protein was isolated from the culture super-
natant by affinity chromatography with Sepharose-bound human
IgA (van Zandbergen, G., and C. van Kooten, unpublished data).
 
Monoclonal Antibodies.
 
The previously described Fc
 
a
 
RI mAbs
My43 (murine IgM), A3, A59, A62, and A77 (all murine IgG1)
were used in this study (33, 34). My43 and A62 were gifts from
Dr. Li Shen (Dartmouth Medical School, Lebanon, NH) and Dr.
Max Cooper (University of Alabama, Birmingham, AL), respec-
tively. A77 was supplied by Medarex Europe (The Netherlands),
and A3 and A59 were purchased from Immunotech (France) and
Research Diagnostics Inc. respectively. The bFc
 
g
 
2R mAb CC-
G24 (murine IgM) was generated by immunizing mice with
bFc
 
g
 
2R protein purified from cattle leukocytes, and the specific-
ity was confirmed by staining COS-7 cells transfected with
cDNA encoding the bFc
 
g
 
2R or bovine Fc
 
g
 
RII (Howard, C.J.,
unpublished data). To obtain new Fc
 
a
 
RI mAbs, female BALB/C
mice were immunized with purified soluble Fc
 
a
 
RI. Splenocytes
isolated from immunized animals were fused with myeloma cells
(SP20) in the presence of 50% polyethylene glycol. The cell sus-
pension was diluted in IMDM supplemented with 10% FCS, hy-
poxanthine (100 
 
m
 
mol), aminopterin (0.4 
 
m
 
M), thymidine (16
 
m
 
M), 500 pg/ml IL-6, 100 U/liter penicillin, and 100 
 
m
 
g/ml
streptomycin. Cells producing antibodies to Fc
 
a
 
RI were sub-
cloned by limiting dilution. Five clones producing mAb to
Fc
 
a
 
RI were expanded and the specificity was determined by
FACS
 
®
 
 analysis (see below). To define the capacity of these new
mAbs to inhibit binding of IgA to Fc
 
a
 
RI, blocking studies were
performed as follows: Fc
 
a
 
RI mAbs or control mAbs of the same
isotype were diluted in FACS buffer and incubated together with
Fc
 
aRI-transfected IIA1.6 cells for 15 min at 48C. Purified human1717 Morton et al.
serum IgA, which had previously been heat-aggregated for 1 h at
638C (aIgA), was then added for 1 h at 48C. Cells were washed
and bound aIgA was detected by incubation with a goat anti–
human IgA F(ab)2-PE polyclonal antibody conjugate (Southern
Biotechnology Associates, Inc.) in FACS® analysis. Isotype control
antibodies for murine IgG1 were purchased from Becton Dickin-
son, and those for murine IgM were provided by Dr. Robert
Burns (Scottish Agricultural Science Agency, Edinburgh, UK).
FACS® Analysis. Cells (5 3 105) were washed twice with
FACS buffer (PBS/0.5% BSA/0.02% azide) and incubated with
either FcaRI mAb (murine IgM or IgG1) culture supernatant or
the appropriate isotype control supernatant for 1 h at 48C. Cells
were then washed twice with FACS buffer and incubated for 1 h
at 48C with either goat anti–mouse (GAM) IgM-FITC conjugate
(1:150 final dilution), or a GAM IgG1-PE conjugate (1:150 final
dilution) (both from Southern Biotechnology Associates, Inc.). In
experiments where GFP1 cells were analyzed for chimeric FcR
expression, a GAM IgG1 Tricolor secondary reagent (1:200 final
dilution) (Caltag Labs.) was used. After washing twice with FACS
buffer, cells were fixed in PBS-buffered 1% (wt/vol) paraformal-
dehyde at 48C and analyzed on a FACScan®. Data acquisition
was conducted with Lysis II software (Becton Dickinson), and
data analysis was performed using WinMDI software (available
from The Scripps Research Institute, La Jolla, CA).
Results
The EC1 Domains of FcaRI and bFcg2R Mediate Ligand
Binding. To map the ligand-binding domains of FcaRI
and bFcg2R, we generated five chimeric receptors as fol-
lows: hEC-bFcg2R, consisting of the two EC domains of
FcaRI fused to the transmembrane/cytoplasmic (TM/C)
domain of bFcg2R; bEC-FcaRI, the two bovine EC
domains fused to the TM/C domain of FcaRI; hEC1-
bFcg2R, the EC1 domain of FcaRI fused to the EC2
TM/C region of bFcg2R; bEC1-FcaRI, the EC1 domain
of bFcg2R joined to the EC2 TM/C region of FcaRI;
and bEC1(1–50)-FcaRI, the first 50 amino acids of bFcg2R
fused at isoleucine 50 to FcaRI (Fig. 1). Together with
wild-type FcaRI and bFcg2R cDNAs, individual chimeric
FcR constructs were transfected to COS-1 cells, and their
cell surface expression was assessed by FACS® analysis and
by a specific binding assay using Ig-coated beads (see Mate-
rials and Methods). Initial experiments revealed the trans-
fection efficiency of individual constructs to be quite vari-
able. The most efficient construct directed expression of
FcaRI on the surface of z30% of COS-1 cells, whereas
the least efficient (bEC1-FcaRI) was expressed by only 3%
of the transfectants (Fig. 2 A). Therefore, we developed a
method to selectively enrich for transiently transfected cells
by cotransfecting a plasmid that directed expression of GFP
(visualized by green fluorescence) together with the chi-
meric FcR constructs. Most GFP1 COS-1 cells cotrans-
Figure 1. Alignment of amino acid sequences of FcaRI (X54150) and
bFcg2R (Z37506). S1 exons are shown from the methionine initiation
codons. Because the gene structure of bFcg2R is unknown, intron–exon
boundaries are shown only for FcaRI. Amino acids that link two FcaRI
exons are underlined, and the exon designation is shown above the se-
quence. Note that exon-linking amino acids are conserved between
FcaRI and bFcg2R. The first 19 amino acids of both sequences are con-
sidered to represent NH2-terminal signal peptides, which are removed
before cell surface expression. Thus, glutamine (Q) 22 is proposed to be
the first amino acid of both mature proteins and therefore is designated
11. Isoleucine (I) 50 is also underlined. Residues of bFcg2R identical to
those of FcaRI are designated (*), and gaps that have been inserted to line
up the sequences are designated (–) (also see reference 7).
Figure 2. Expression of chi-
meric FcR by COS-1 cells. (A)
Cos-1 cells were transfected with
the indicated constructs 2 d be-
fore harvesting and FACS® anal-
ysis. Cells were stained with ei-
ther FcaRI EC2-specific mAb
A62 (mouse IgG1) (bottom pan-
els) or an appropriate isotype
control (top panels), followed by
a GAM IgG1 Tricolor reagent.
Numbers in the top right corners
of the plots refer to the percent-
age of positive cells. (B) Enrich-
ment of FcaRI expression in
COS-1 cells cotransfected with
GFP. Cells transfected with both
FcaRI and GFP were stained
with FcaRI EC2-specific mAb A62 followed by GAM IgG1 Tricolor reagent and analyzed by FACS®. More than 60% of the GFP1 cells also express
FcaRI. (C) Rosette formation by COS-1 cells cotransfected with both FcaRI and GFP and exposed to hIgA-coated beads. Rosettes were quantified as
specified in Materials and Methods. Black bar, total number of cells counted; white bar, total number of GFP1 cells assessed by fluorescent microscopy;
gray bar, number of GFP1 cells forming rosettes. Results shown are representative of three separate experiments.1718 FcaRI and Bovine Fcg2R Bind Ligand Via EC1
fected with FcaRI were recognized by mAb A62 (Fig. 2 B),
and formed rosettes with hIgA-coated beads (Fig. 2 C). By
this procedure we obtained an approximately twofold en-
richment of chimeric FcR-expressing cells, which in the
case of FcaRI resulted in .60% of cells being reactive with
FcaRI mAb and further able to form rosettes with hIgA
coated beads (Fig. 2, B and C). It should be noted that
GFP2 COS-1 almost never formed rosettes, most likely
because transfectants expressing FcaRI alone accounted for
only z1% of the total cells (Fig. 2 B). We, furthermore,
demonstrated the specificity of our binding assay by using
blocking mAbs specific for FcaRI or bFcg2R to inhibit
rosette formation (Fig. 3). The finding that the inhibition
obtained with My43 was only partial (z50%) was most
likely explained by the use of culture supernatant other
than a higher concentration of purified antibody which was
not available.
FcaRI does not bind bIgG2, and bFcg2R does not bind
hIgA (reference 7 and this paper); accordingly, we neither
observed rosettes when hIgA-coated beads were mixed
with bFcg2R transfectants, nor when bIgG2-coated beads
were mixed with FcaRI transfectants (Fig. 4). Binding
studies with COS-1 cells enriched for FcR expression as
described above, showed not unexpectedly that wild-type
FcaRI and bFcgR2 transfectants produced the highest lev-
els of rosette formation with hIgA- and bIgG2-coated
beads, respectively (Fig. 4). Transfectants expressing chime-
ras coding for the entire EC portions of the receptors
(hEC-bFcg2R and bEC-FcaRI) bound their respective
Ig-coated beads efficiently, although at a slightly lower
level than their wild-type counterparts (Fig. 4). The fact
that the hEC1-bFcg2R chimera retained IgA-binding ca-
pacity demonstrated that the binding site of FcaRI lies
within the membrane-distal EC1 domain. Furthermore,
because this chimera did not form rosettes with bIgG2-
coated beads, our finding further suggested that the binding
site for bIgG2 in bFcg2R was not located within the EC2
domain of this receptor. Conversely, the bEC1-FcaRI chi-
mera did form rosettes with bIgG2-coated beads, but not
with beads coated with hIgA.
Altogether these results showed that, in common with
FcaRI, the ligand-binding site of bFcg2R appeared to
lie within the EC1 domain. It should be noted, however,
that the level of binding obtained with the two EC1 chi-
meras (hEC1-bFcg2R and bEC1-FcaRI) was reduced
when compared with the wild-type receptors, and the EC
chimeras (hEC-bFcg2R and bEC-FcaRI) (Fig. 4). Futher-
more, to better localize the Ig-binding sites of these two
receptors, a further chimera was constructed in which the
first 50 amino acids of the EC1 domain were from bFcg2R,
while the remaining EC1 (49 amino acids) and the rest of
the receptor were from FcaRI [bEC1(1–50)-FcaRI]. Al-
though this chimera was expressed at the cell surface and
could be recognized by the majority of FcaRI mAb, it
bound neither hIgA- nor bIgG2-coated beads.
EC1-specific Antibodies Block FcaRI Binding of IgA. To con-
firm that the IgA-binding site of FcaRI lies within the EC1
domain, we mapped the specific epitopes for a number of
blocking and nonblocking mAbs. Of the previously de-
scribed FcaRI mAbs, only My43 (murine IgM) was able to
block the binding of hIgA to FcaRI (33). Four others (A3,
A59, A62, and A77, all murine IgG1) did not inhibit bind-
ing (34). We also included a number of new FcaRI mAbs
(2E6, 2D11, 7G4, 2H8, and 7D7, all murine IgG1), raised
Figure 3. Specificity of the bead rosetting assays. COS-1 cells were
cotransfected with the indicated FcR construct together with pCMV-
GFP. GFP1 cells were purified as described in Materials and Methods and
incubated with the relevant murine IgM-blocking mAb or an irrelevant
murine IgM control mAb for 30 min before addition of Ig-coated beads.
Results are shown as percentage of inhibition of rosette formation when
compared with transfectants that were not incubated with mAb before
rosetting analysis. Results shown are representative of two experiments.
Figure 4. Rosette formation by FcR/GFP cotransfected COS-1 cells.
Schematic representation of wild-type and chimeric FcRs. Unshaded re-
gions are derived from FcaRI, shaded regions from bFcg2R. S, signal
peptide; EC1, extracellular domain 1; EC2, extracellular domain 2;
TM/C, transmembrane/cytoplasmic tail. GFP1 transfectants were puri-
fied from COS-1 cells cotransfected with GFP and FcR constructs as de-
scribed. Ig-binding to FcRs coexpressed with GFP was assessed by roset-
ting with either hIgA- or bIgG2-coated beads. More than 200 cells were
counted for each determination, and the number of cells binding four or
more Ig-coated beads is expressed as percentage rosette formation. Re-
sults are representative of three separate experiments.1719 Morton et al.
against a soluble form of FcaRI. These mAbs were shown to
be specific for FcaRI by reaction with IIA1.6 cells express-
ing this receptor (Fig. 5 A). They were next assayed for abil-
ity to block binding of heat-aggregated hIgA to FcaRI:
mAbs 2E6, 2D11, 7G4, and 2H8 produced such inhibition
while 7D7 did not (Fig. 5 B). Accordingly, we presumed
that the blocking mAbs would prove to be EC1-specific,
whereas the nonblocking ones would be EC2 specific.
To test this hypothesis, we screened the reactivity of all
mAbs against the panel of chimeric FcR expressed in
COS-1 cells by FACS® analysis. Indeed, all mAbs capable
of blocking the binding of heat-aggregated hIgA to FcaRI
(Fig. 5 B), mapped to the EC1 domain (Fig. 5 C). Also, all
nonblocking mAbs were directed against the EC2 domain,
except for mAb A3 that apparently recognized an epitope
depending on parts of both domains. Unfortunately, be-
cause only one mAb against bFcg2R was available, a simi-
lar detailed study could not be performed for this receptor.
We showed that mAb CC-G24 only recognized wild-type
bFcg2R and the bEC-FcaRI chimera (Fig. 5 C). Thus,
like mAb A3, it is most likely directed against a conforma-
tional epitope depending on both EC1 and EC2.
Discussion
By means of a panel of chimeric FcRs, we identified
conclusively for the first time the ligand-binding sites of
FcaRI and bFcg2R. Surprisingly, these sites were found to
be located in the EC1 domains. FcaRI and bFcg2R are
highly homologous both at the protein and nucleotide
level (41 and 56% identity, respectively), but show much
less homology with other human and bovine FcRs (7).
This suggests that FcaRI and bFcg2R evolved from a
common ancestral gene (also shared by KIR, ILT, MIR,
LIR, LAIR-1, HM18, PIR, and gp49B1 genes) and not
shared by other human or bovine FcRs (7). Mapping of the
bFcg2R gene to bovine chromosome 18, which corre-
sponds to human chromosome 19, further supports this no-
tion (35).
Our finding that the Ig-binding sites of both FcaRI and
bFcg2R are located within their EC1 domains, was based
on the fact that rosetting with Ig-coated beads was only
seen for the corresponding FcaRI or bFcg2R EC1 chi-
mera. In both cases, however, a reduction in binding activ-
ity was seen compared with that obtained for the wild-type
receptors and for the comparable EC chimeras (Fig. 4). Al-
though these differences in part may be attributed to the
expression levels of individual constructs (especially for the
bEC1-FcaRI chimera, see above), it is also possible that
the EC2 domains and membrane-proximal regions of
the receptors contribute either directly (by forming “sec-
ondary” contact sites) or indirectly (by preserving three-
dimensional structure) to the affinity and stability of the
ligand interactions. This would be analogous to the activity
of other two-domain FcRs, namely FcgRII, FcgRIII, and
FceRI in which the ligand-binding sites are located in
the membrane-proximal EC2 domains, whereas structures
within the EC1 domains contribute to the binding process
(29, 30).
It should also be noted that the region of hIgA interact-
ing with FcaRI has recently been mapped to the Ca2/
Ca3 boundary (36). This is in contrast to the region of hu-
man IgG responsible for interaction with FcgRs, which is
proposed to lie much closer to the hinge (30). Therefore,
in terms of the evolution of Ig/FcR interactions, it should
be interesting to map the region of bIgG2 that binds to
bFcg2R. Because recombinant bIgG2 is available, experi-
ments can readily be designed to determine whether this
region lies close to the hinge region as in human IgG or in
a position analogous to that of hIgA (37).
To substantiate our observation that hIgA binds to the
EC1 domain of FcaRI, we mapped the epitopes for a
panel of blocking and nonblocking FcaRI mAbs that
bound equally to the EC parts of wild-type FcaRI and the
Figure 5. (A) FACS® analysis of newly produced mAbs to FcaRI compared with mAb A77 of similar specificity. FcaRI-expressing murine B cells
(IIA1.6) were incubated with mAbs as indicated (white peaks) or with concentration and isotype-matched control mAbs (hatched peaks), followed by a
GAM IgG1–PE conjugate. (B) FcaRI-expressing IIA1.6 cells were incubated without (left panel) or with mAbs as indicated, followed by heat-aggre-
gated hIgA (aIgA). After 1 h at 48C, cells were washed and bound hIgA was detected by incubation with goat anti–human IgA F(ab)2-PE conjugate
(white peaks). Cells incubated with only the secondary reagent served as negative controls (hatched peaks). (C) Reactivity of chimeras (left) with a panel
of FcaR and bFcg2R mAb (top) as measured by FACS® analysis. Binding was graded as follows: 1, strong binding; 1/2, weak binding; 2, no binding.1720 FcaRI and Bovine Fcg2R Bind Ligand Via EC1
hEC-Fcg2R chimera. The nonblocking mAbs (A59, A62,
A77, and 7D7) were shown to react with the membrane-
proximal EC2 domain because they bound only to wild-
type FcaRI and the hEC-bFcg2R, bEC1-FcaRI, and
bEC1(1–50)-FcaRI chimeras. The only exception was the
nonblocking mAb A3 that bound only to wild-type FcaRI
and the hEC-bFcg2R and bEC1(1–50)-FcaRI chimeras,
suggesting that its epitope is conformational and depends
on regions of both EC1 and EC2 (similar to the bFcg2R
mAb CC-G24; see Results section). In contrast, all block-
ing mAbs (My43, 2E6, 2D11, 7G4, and 2H8) were shown
to react with the EC1 domain of FcaRI because their
binding activity was retained with the hEC1-bFcg2R chi-
mera. The epitopes recognized by My43 and 2D11 were
further localized to the region of EC1 directly adjacent to
EC2, because they were shown to bind the bEC1(1–50)-
FcaRI chimera. 2E6 and 2H8 on the other hand, bound
only weakly to this chimera, whereas 7G4 did not bind at
all. Similar mapping studies with blocking mAbs have pre-
viously been used to localize the IgG-binding sites of
FcgRII and FcgRIII to their EC2 domains (25, 27).
A number of FcaRI mRNAs have been isolated and
shown to encode splice variants of the receptor (38–41).
One such report described cell surface expression of an FcaRI
variant that lacked the complete EC2 domain, and sug-
gested the EC1 domain to be involved in hIgA binding
(40). However, in contrast to our results, mAb My43 was
proposed to react with EC2, and mAb A59 with EC1. We
believe that observation to be spurious either due to incor-
rect cell surface expression of the splice variant and/or ab-
errant receptor structure caused by lack of the complete
EC2 domain. This possibility was supported by our attempts
to express various FcaRI splice variants in COS cells with
no success (38). Additionally, chimeras constructed between
FcaRI and FcgRII were not expressed efficiently (Morton,
H.C., and J.G.J. van de Winkel, unpublished observations),
possibly reflecting a degree of structural incompatibility be-
tween these two FcRs. In fact, our unsuccessful experience
with those approaches led us to construct chimeras be-
tween FcaRI and bFcg2R as reported here, because their
levels of homology (and hence presumably their overall
structure) are more similar than for other FcRs. Thus swap-
ping of highly homologous regions should have minimal af-
fect on the overall structural integrity of the resultant chi-
meras. Therefore, we feel that the present approach is more
physiological than previous attempts to this end.
The surprising difference seen between the ligand-bind-
ing sites of FcaRI and bFcg2R versus those of other leuko-
cyte FcgRs and FceRI may have interesting implications in
terms of Ig interactions. As mentioned above, this disparity
could simply reflect the proposed evolution of FcaRI and
bFcg2R from an ancestral gene distinct from that giving
rise to other FcgRs and FceRI. This notion is supported by
the observation that residues within the membrane-distal
domain of two KIR proteins determine their ability to bind
to their respective ligands, the two groups of HLA-C al-
lotypes (42). Moreover, due to their high levels of ho-
mology, the three-dimensional structure of FcaRI and
bFcg2R might more closely resemble that of the KIR pro-
teins than that of more distantly related FcRs (43). Indeed,
more detailed mutational analysis, directed by modeling
studies using the recently published three dimensional
structure of the p58 KIR as a template for the protein
backbones of FcaRI and bFcg2R, are currently underway
in our laboratory to further localize the Ig-binding sites
within these two receptors.
An alternative evolutionary explanation possibly applica-
ble at least for FcaRI might be that its ligand-binding site
developed to ensure interaction with all molecular forms of
IgA: monomeric IgA, dimeric IgA (including J chain), and
secretory IgA (including J chain and secretory component).
FcaRI is reported to bind all these ligand variants (44, 45).
Therefore, because the site of interaction with FcaRI at the
Ca2/Ca3 boundary appears to be accessible to the receptor
in all these forms of IgA, FcaRI could have evolved to ac-
complish this interaction via its EC1 domain to avoid poten-
tial problems of steric hindrance of a more membrane-prox-
imal binding site in relation to large IgA polymers.
In conclusion, we have shown that the closely related
FcaRI and bFcg2R bind their ligands via sites located in
their membrane-proximal EC1 domains. The difference in
the Ig-binding sites of these two receptors versus other leu-
kocyte FcgRs and FceRI, may reflect the proposed diver-
gent evolutionary pathway from a distinct genetic precur-
sor, or (at least in the case of FcaRI) a specific adaptation
for efficient interaction with large molecular forms of IgA.
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